NCT06582524已完成3 期
A Phase 3 Open-Label Study of Safety, Pharmacokinetics, and Activity of Weekly Subcutaneous Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 3
- 试验地点
- 5
- 主要终点
- To evaluate the effect of pegzilarginase
研究概览
简要总结
This is an open-label, multicentre study to evaluate the safety, PK, and activity (PD) of weekly subcutaneous (SC) administration of pegzilarginase in subjects with ARG1-D who are < 24 months of age. The study consists of a screening period of up to 4 weeks, a subsequent 12-week treatment period, and a safety follow-up period of 8 weeks.
详细描述
CAEB1102-301A is an open-label, single-arm, non-controlled, repeat dosing, multicentre study to evaluate the safety, PK, and activity (PD) of weekly SC administration of pegzilarginase over 12 weeks in subjects with ARG1-D who are < 24 months of age.
This study will consist of:
- A screening period of up to 4 weeks to ensure the subjects meet the study eligibility criteria and establish baseline plasma arginine
- A treatment period of 12 weeks
- A safety follow-up period of 8 weeks with visits 1 week and 8 weeks after the last dose.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Day 至 24 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects must be < 24 months of age on the date of informed consent
- •Confirmed diagnosis of ARG1-D documented in medical records by at least 1 of the following methods:
- •elevated plasma arginine levels
- •a mutation analysis revealing a pathogenic variant
- •red blood cell (RBC) arginase activity
- •Subjects must weigh > 8 kg due to clinical trial related blood collection volumes required
- •Written informed consent by parent/legal guardian, in accordance with national stipulations, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
- •At least one value of plasma arginine ≥ 180 μM during screening
- •Documented confirmation from the Investigator and/or dietitian that the subject can:
- •attempt to maintain a stable, age-appropriate level of protein consumption, including natural protein, and EAA supplementation within approximately ± 15% of dietitian recommended diet
- •attempt to maintain current use of ammonia scavengers, if prescribed
排除标准
- •Other medical condition(s) or comorbidity(ies) that, in the opinion of the Investigator, would interfere with study compliance or data interpretation
- •Hyperammonaemic episode (plasma ammonia levels > 100 μM) with ≥ 1 symptom related to hyperammonaemia requiring hospitalisation or emergency room management within the 4 weeks before the first dose of study drug
- •Active infection requiring anti-infective therapy within < 2 weeks before first dose of study drug
- •Known active infection with human immunodeficiency virus, hepatitis B, or hepatitis C
- •History of hypersensitivity to polyethylene glycol (PEG) or any of the excipients included in the study drug that, in the judgment of the Investigator, puts the subject at unacceptable risk for AEs
- •Currently participating in another therapeutic clinical study or has received any investigational agent within 30 days (or 5 half-lives, whichever is longer) prior to first dose of study drug
- •Previous liver or haematopoietic stem cell transplant
- •Use of botulinum toxin within 16 weeks prior to first dose
研究组 & 干预措施
Weekly subcutaneous (SC) administration of pegzilarginase
Experimental
All subjects will receive a once weekly (QW) SC dose of pegzilarginase for 12 weeks
干预措施: Pegzilarginase (Drug)
结局指标
主要结局
To evaluate the effect of pegzilarginase
时间窗: From baseline up to 12 weeks
To evaluate the effect of pegzilarginase on plasma arginine concentrations in subjects \<24 months of age with arginase 1 deficiency (ARG1-D)
次要结局
- To evaluate the safety of pegzilarginase(From baseline up to 12 weeks)
- To characterize the pharmacokinetic (PK) profile of pegzilarginase(From baseline up to 12 weeks)
- To evaluate the pharmacodynamic (PD) response of pegzilarginase(From baseline up to 12 weeks)
- To describe changes in physical function(From baseline up to 12 weeks)
研究者
研究点 (5)
Loading locations...
相似试验
进行中（未招募）
3 期
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPDPompe Disease (Late-onset)NCT03911505Amicus Therapeutics21
招募中
3 期
A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18Glycogen Storage Disease Type II Infantile OnsetNCT04808505Amicus Therapeutics36
已完成
3 期
The Effects of Infliximab Versus Methotrexate in the Treatment of Moderate to Severe Psoriasis (Study P04271AM2)(COMPLETED)PsoriasisNCT00251641Merck Sharp & Dohme LLC868
招募中
3 期
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo NodularisPrurigo NodularisNCT06293053Sanofi18
已完成
1 期
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With LupusCutaneous LupusSystemic Lupus ErythematosusNCT03288324Children's Hospital Medical Center, Cincinnati13